



MARKET RELEASE

9 June 2017

Proteomics International Laboratories Limited

TRADING HALT

The securities of Proteomics International Laboratories Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Wednesday, 14 June 2017, or when the announcement is released to the market.

Security Code: PIQ

Mauro Piccini
Senior Adviser, Listings Compliance (Perth)



Proteomics International

LABORATORIES LTD

9 June 2017

ASX Compliance Pty Ltd
Level 40 Central Park
152-158 St George's Terrace
PERTH WA 6000
Attn: Mr Mauro Piccini

by email: tradinghaltspert@asx.com.au

Dear Mr Piccini

REQUEST FOR TRADING HALT

In accordance with ASX Listing Rule 17.1, Proteomics International Laboratories Ltd (ASX:PIQ) (the **Company**) requests a trading halt of its securities pending the release of an announcement of the results from the PromarkerD clinical validation study which will be presented at the American Diabetes Association conference on Saturday, 10 June 2017, in the USA.

The Company requests the trading halt remain in place until the earlier of such time as it makes an announcement to the market in relation to the results from the clinical validation study and the commencement of trading on Wednesday, 14 June 2017.

The Company is not aware of any reason why the request should not be granted, nor of any other relevant information in relation to this request.

Yours sincerely

Karen Logan
Company Secretary

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com